BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from its Chairman, Richard Staelin, PhD, highlighting sales growth, cost control, and strategic progress. The company reported a small profit for calendar year 2025, attributing this to disciplined cost control measures, including relocating offices and reducing staff to align with operational needs.
Revenue-generating initiatives include targeted advertising campaigns directed at medical professionals and healthcare providers to expand clinical awareness of RecoveryRx among surgeons, pain specialists, and rehabilitation providers. The company also expanded consumer-focused social media advertising targeting Generation X consumers seeking drug-free solutions for chronic musculoskeletal pain. As a result, BioElectronics reported an increase in monthly sales in both the OTC and professional markets.
The company continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The objective is to participate in a postoperative clinical study that may support future qualification for reimbursement under the federal NO PAIN Act initiative, which could drive broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, BioElectronics is working with legal counsel in Singapore and funders in China regarding arbitration proceedings involving a former distributor believed to have breached contractual obligations. The company remains committed to protecting its intellectual property and contractual rights.
BioElectronics also reported progress in its strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, with Electrome issuing its initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform. This milestone provides another pathway to increase consumer awareness and access to FDA-cleared, drug-free pain therapy products.
Despite challenges faced by emerging medical technology companies, BioElectronics remains encouraged by growing interest in non-drug pain management solutions. The company believes it is well positioned within the evolving electroceutical and non-opioid pain management markets and intends to continue advancing initiatives that support sustainable growth.
For more information, visit https://www.bielcorp.com/.
